DSSG Group: Lung

Stage IV NSCLC, fit for thoracic radiotherapy without symptoms requireing immediate radiotherapy.
There are 2 Candidate Specific Trials running under the TOURIST Platform;
QUARTZ Study: This trial arm will recruit patients who are not reciving systemic treatment
PRINCE Study: This trial will recruit patients who are reciving systemic treatment

Aim of the PRINCE Study: work out the effect of early high dose radiotherapy to the chest area on symptoms, disease, progression, length and Quality of Life. It will also assess the side effects and safety of early high dose radiotherapy to the chest area and identify potential barriers, evaluate and explain the treatment and outcomes and highlight issues from the patient perspective.
Aim of QUARTZ Study: work out the effect that low-dose radiotherapy to the chest area on symptoms, disease, progression, length and Quality of Life. It will also assess the side effects and safety of early high dose radiotherapy to the chest area and identify potential barriers, evaluate and explain the treatment and outcomes and highlight issues from the patient perspective.

Relapsed Small Cell Lung Cancer (SCLC)

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Previously Untreated, KRAS G12C-Positive, Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

A Phase III, Randomised, Open-label Study Evaluating the Efficacy and Safety of Divarasib plus Pembrolizumab versus Pembrolizumab plus Pemetrexed and Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Positive, Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

For patients with early-stage non-small cell lung cancer (NSCLC) that has been removed by surgery and who have not been treated with chemotherapy after surgery

The purpose of the ARCH study is to find out whether immunotherapy with cemiplimab helps reduce the chance of lung cancer recurring after surgery, if chemotherapy cannot be given.

PD-L1 Metastatic NSCLC

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Previously Treated, locally advanced or metastatic RAS-mutant NSCLC

RASolve 301 is a global, randomized, open-label, Phase 3 study designed to evaluate the efficacy and safety of daraxonrasib compared to docetaxel in patients with previously treated, locally advanced or metastatic, RAS-mutant NSCLC

Resectable Stage II to IIIB (N2) NSCLC

The goal of this study is to learn if people who receive V940 and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving V940 and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumours did not respond completely to treatment before surgery (neoadjuvant treatment).

Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of the study is to compare the efficacy of Nivolumab and Relatlimab Plus Chemotherapy Vs Pembrolizumab Plus Chemo for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Stage IIB-IIIB (N2) resectable NSCLC

The purpose of this study is to evaluate the efficacy and safety of adding adjuvant durvalumab after neoadjuvant chemo plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Non-squamous Non-small Cell Lung Cancer

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation